PTN Inhibitors
PTN inhibitors represent a diverse class of chemicals that modulate the expression and function of Pleiotrophin (PTN), primarily by targeting its binding to cell surfaces and associated signaling pathways. Suramin, a direct PTN inhibitor, disrupts the interaction between PTN and cell surface receptors, inhibiting downstream signaling and modulating cellular responses dependent on PTN activity. Cisplatin, an indirect inhibitor, induces cellular stress and DNA damage, triggering downstream signaling cascades that negatively impact PTN expression and function, influencing cellular processes. Heparin, another indirect inhibitor, interferes with PTN binding to cell surface heparan sulfate proteoglycans, disrupting the interaction between PTN and its receptors. Similarly, SU5402, a selective FGFR inhibitor, indirectly inhibits PTN by targeting the FGFR signaling pathway, disrupting the interaction between PTN and FGFRs. These actions lead to downstream signaling modulation and influence cellular responses dependent on PTN activity.
RPI-1, a small molecule, directly inhibits PTN by interfering with its binding to cell surfaces, similar to Suramin. PI-103, a dual PI3K/mTOR inhibitor, indirectly inhibits PTN by targeting the PI3K/Akt/mTOR signaling pathway, disrupting signaling downstream of PTN and modulating cellular responses. PD173074, a selective FGFR inhibitor, and SB-431542, a TGF-β receptor inhibitor, also indirectly inhibit PTN by disrupting signaling pathways associated with PTN. Lomustine, an alkylating agent, induces cellular stress and DNA damage, impacting PTN expression and function. Pentosan polysulfate interferes with PTN binding to heparan sulfate proteoglycans, similar to Heparin. Sunitinib, a multi-tyrosine kinase inhibitor, indirectly inhibits PTN by targeting multiple signaling pathways, including VEGFR and PDGFR, influencing cellular responses dependent on PTN activity. In summary, PTN inhibitors offer a multifaceted approach to understanding and manipulating the intricate regulatory networks involving PTN, providing valuable insights into the molecular mechanisms governing cellular processes influenced by PTN activity.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Suramin, a polyanionic compound, acts as a direct PTN inhibitor by disrupting its binding to cell surfaces. It interferes with the interaction between PTN and cell surface receptors, inhibiting downstream signaling pathways and modulating cellular responses dependent on PTN activity. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin, a platinum-based chemotherapeutic agent, indirectly inhibits PTN by inducing cellular stress and DNA damage. This stress response triggers downstream signaling cascades that can negatively impact PTN expression and function, influencing cellular processes dependent on PTN activity. | ||||||
Heparin | 9005-49-6 | sc-507344 | 25 mg | $117.00 | 1 | |
Heparin sodium salt, an anticoagulant, indirectly inhibits PTN by disrupting its binding to cell surface heparan sulfate proteoglycans. This interference hinders the interaction between PTN and its receptors, leading to downstream signaling modulation and influencing cellular responses dependent on PTN activity. | ||||||
SU 5402 | 215543-92-3 | sc-204308 sc-204308A | 1 mg 5 mg | $62.00 $96.00 | 36 | |
SU5402, a selective FGFR inhibitor, indirectly inhibits PTN by targeting the FGFR signaling pathway. PTN interacts with FGFRs, and SU5402 disrupts this interaction, leading to downstream signaling modulation and influencing cellular processes dependent on PTN activity. | ||||||
PI-103 | 371935-74-9 | sc-203193 sc-203193A | 1 mg 5 mg | $32.00 $128.00 | 3 | |
PI-103, a dual PI3K/mTOR inhibitor, indirectly inhibits PTN by targeting the PI3K/Akt/mTOR signaling pathway. PTN is involved in this pathway, and PI-103 disrupts signaling downstream of PTN, leading to modulation of cellular responses dependent on PTN activity. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074, a selective FGFR inhibitor, indirectly inhibits PTN by targeting the FGFR signaling pathway. PTN interacts with FGFRs, and PD173074 disrupts this interaction, leading to downstream signaling modulation and influencing cellular processes dependent on PTN activity. | ||||||
Lomustine | 13010-47-4 | sc-202697 | 50 mg | $99.00 | 2 | |
Lomustine, an alkylating agent, indirectly inhibits PTN by inducing cellular stress and DNA damage. This stress response triggers downstream signaling cascades that can negatively impact PTN expression and function, influencing cellular processes dependent on PTN activity. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542, a TGF-β receptor inhibitor, indirectly inhibits PTN by targeting the TGF-β signaling pathway. PTN is involved in this pathway, and SB-431542 disrupts signaling downstream of PTN, leading to modulation of cellular responses dependent on PTN activity. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib, a multi-tyrosine kinase inhibitor, indirectly inhibits PTN by targeting multiple signaling pathways, including VEGFR and PDGFR. PTN is involved in these pathways, and Sunitinib disrupts signaling downstream of PTN, leading to modulation of cellular responses dependent on PTN activity. | ||||||